13Jun/13

XOMA Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma … – PipelineReview.com (press release)

XOMA Initiates Pilot Trial Studying Gevokizumab in Patients With Pyoderma
PipelineReview.com (press release)
BERKELEY, CA, USA I June 13, 2013 I XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has opened enrollment in a pilot study to determine gevokizumab’s potential to treat acute 

and more »

13Jun/13

MD Anderson Researcher Reports Idelalisib and Rituximab Produce Responses … – BioNews Texas


BioNews Texas

MD Anderson Researcher Reports Idelalisib and Rituximab Produce Responses
BioNews Texas
Idelalisib Dr. Susan M. O’Brien from the University of Texas MD Anderson Cancer Center in Houston reported that pairing rituximab with the experimental agent idelalisib can improve the management of small lymphocytic lymphoma or treatment- naive 

13Jun/13

Chronic Kidney Disease: Reducing Risks of Progression– Prismic … – The Herald | HeraldOnline.com

Chronic Kidney Disease: Reducing Risks of Progression– Prismic
The Herald | HeraldOnline.com
SCOTTSDALE, Ariz., June 13, 2013 — /PRNewswire/ — Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based pharmaceutical company, today announced that it has secured exclusive licensing rights to Palmitoylethanolamide (PEA), including the 

and more »